# StarRise Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/starrise-biotech

- Industry: Healthcare
- Headquarters: Chengdu, China
- Latest round: Angel (Aug 25, 2025)
- Investors on record: 2

## About

Founded in 2025 and based in Chengdu, China, StarRise Biotech is a high-tech enterprise focused on biopharmaceutical research and development. StarRui Jingxuan focuses on the R&D and commercialization of integrated radiopharmaceuticals for pan-tumor diagnosis and treatment, and specializes in the development of radioligand therapy (RLT), achieving integrated, precise diagnosis and treatment of tumors through the coupling of radionuclides with targeting ligands. The company generates revenue by developing innovative drugs and biotechnologies, and providing safer and more effective treatment options for patients worldwide. In August 2025, StarRise Biotech raised an Angel funding co-invested by new investors BIO-TOWN Capital and Shanghai Fosun Pharmaceutical (Group). The company will advance the company's biopharmaceutical R&D projects and build its team.

## Funding rounds

- Angel, Aug 25, 2025 — Shanghai Fosun Pharmaceutical (Group), BIO-TOWN Capital

## Investors

- Shanghai Fosun Pharmaceutical (Group) — Angel
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Angel